Rho-kinase inhibitors to deplete age-associated B cells in systemic autoimmunity
Immunol Lett. 2023 Sep 7;262:36-38. doi: 10.1016/j.imlet.2023.09.004. Online ahead of print.NO ABSTRACTPMID:37689314 | DOI:10.1016/j.imlet.2023.09.004 (Source: Immunology Letters)
Source: Immunology Letters - September 9, 2023 Category: Allergy & Immunology Authors: Athanasios Sachinidis Alexandros Garyfallos Source Type: research
Modulation of Oxidized Low-density Lipoprotein-Affected Macrophage Efferocytosis by Mitochondrial Calcium Uniporter in a Murine Model
CONCLUSIONS: In this study, we found that MCU inhibition modulated intracytoplasmic Ca2+ concentration, improved impaired Mø efferocytosis, and reduced ROS generation. Macrophage efferocytosis removed apoptotic cells and prevented the release of inflammatory factor and foam cell formation, and this can be a potential new therapeutic target for alleviating atherosclerosis.PMID:37689315 | DOI:10.1016/j.imlet.2023.09.003 (Source: Immunology Letters)
Source: Immunology Letters - September 9, 2023 Category: Allergy & Immunology Authors: Na Lu Jun-Fan Zhu He-Fan Lv Hai-Peng Zhang Peng-le Wang Jing-Jing Yang Xian-Wei Wang Source Type: research
Rho-kinase inhibitors to deplete age-associated B cells in systemic autoimmunity
Immunol Lett. 2023 Sep 7;262:36-38. doi: 10.1016/j.imlet.2023.09.004. Online ahead of print.NO ABSTRACTPMID:37689314 | DOI:10.1016/j.imlet.2023.09.004 (Source: Immunology Letters)
Source: Immunology Letters - September 9, 2023 Category: Allergy & Immunology Authors: Athanasios Sachinidis Alexandros Garyfallos Source Type: research
Modulation of Oxidized Low-density Lipoprotein-Affected Macrophage Efferocytosis by Mitochondrial Calcium Uniporter in a Murine Model
CONCLUSIONS: In this study, we found that MCU inhibition modulated intracytoplasmic Ca2+ concentration, improved impaired Mø efferocytosis, and reduced ROS generation. Macrophage efferocytosis removed apoptotic cells and prevented the release of inflammatory factor and foam cell formation, and this can be a potential new therapeutic target for alleviating atherosclerosis.PMID:37689315 | DOI:10.1016/j.imlet.2023.09.003 (Source: Immunology Letters)
Source: Immunology Letters - September 9, 2023 Category: Allergy & Immunology Authors: Na Lu Jun-Fan Zhu He-Fan Lv Hai-Peng Zhang Peng-le Wang Jing-Jing Yang Xian-Wei Wang Source Type: research
Rho-kinase inhibitors to deplete age-associated B cells in systemic autoimmunity
Immunol Lett. 2023 Sep 7:S0165-2478(23)00147-5. doi: 10.1016/j.imlet.2023.09.004. Online ahead of print.NO ABSTRACTPMID:37689314 | DOI:10.1016/j.imlet.2023.09.004 (Source: Immunology Letters)
Source: Immunology Letters - September 9, 2023 Category: Allergy & Immunology Authors: Athanasios Sachinidis Alexandros Garyfallos Source Type: research
Modulation of Oxidized Low-density Lipoprotein-Affected Macrophage Efferocytosis by Mitochondrial Calcium Uniporter in a Murine Model
CONCLUSIONS: In this study, we found that MCU inhibition modulated intracytoplasmic Ca2+ concentration, improved impaired Mø efferocytosis, and reduced ROS generation. Macrophage efferocytosis removed apoptotic cells and prevented the release of inflammatory factor and foam cell formation, and this can be a potential new therapeutic target for alleviating atherosclerosis.PMID:37689315 | DOI:10.1016/j.imlet.2023.09.003 (Source: Immunology Letters)
Source: Immunology Letters - September 9, 2023 Category: Allergy & Immunology Authors: Na Lu Jun-Fan Zhu He-Fan Lv Hai-Peng Zhang Peng-le Wang Jing-Jing Yang Xian-Wei Wang Source Type: research
USE OF RECOMBINANT S1 PROTEIN WITH hFc FOR ANALYSIS OF SARS-COV-2 ADSORPTION AND EVALUATION OF DRUGS THAT INHIBIT ENTRY INTO VERO E6 CELLS
Immunol Lett. 2023 Sep 6:S0165-2478(23)00145-1. doi: 10.1016/j.imlet.2023.09.002. Online ahead of print.ABSTRACTThe significant number of deaths and cases of infection by the new coronavirus SARS-CoV-2 requires an urgent demand for effective and available drugs for the treatment of COVID-19.However, the need for biosafety level 3 (NB-3) laboratories for experiments with the virus has made it very difficult for such research to meet this demand. It is known that angiotensin-converting enzyme 2 (ACE2), located on the surface of host cells, is the viral receptor for the spike (S) protein of SARS-CoV-2. This protein is a tetra...
Source: Immunology Letters - September 8, 2023 Category: Allergy & Immunology Authors: J éssica Carla Martins Couto Ta ís Vidal Eduardo Reichert Decker Janio M Santurio Carlos Fernando de Mello Micheli Mainardi Pillat Source Type: research
USE OF RECOMBINANT S1 PROTEIN WITH hFc FOR ANALYSIS OF SARS-COV-2 ADSORPTION AND EVALUATION OF DRUGS THAT INHIBIT ENTRY INTO VERO E6 CELLS
Immunol Lett. 2023 Sep 6:S0165-2478(23)00145-1. doi: 10.1016/j.imlet.2023.09.002. Online ahead of print.ABSTRACTThe significant number of deaths and cases of infection by the new coronavirus SARS-CoV-2 requires an urgent demand for effective and available drugs for the treatment of COVID-19.However, the need for biosafety level 3 (NB-3) laboratories for experiments with the virus has made it very difficult for such research to meet this demand. It is known that angiotensin-converting enzyme 2 (ACE2), located on the surface of host cells, is the viral receptor for the spike (S) protein of SARS-CoV-2. This protein is a tetra...
Source: Immunology Letters - September 8, 2023 Category: Allergy & Immunology Authors: J éssica Carla Martins Couto Ta ís Vidal Eduardo Reichert Decker Janio M Santurio Carlos Fernando de Mello Micheli Mainardi Pillat Source Type: research
Leveraging microRNAs for cellular therapy
Immunol Lett. 2023 Sep 1:S0165-2478(23)00143-8. doi: 10.1016/j.imlet.2023.08.005. Online ahead of print.ABSTRACTOwing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thu...
Source: Immunology Letters - September 3, 2023 Category: Allergy & Immunology Authors: Marko Hasiuk Marianne D ölz Romina Marone Lukas T Jeker Source Type: research
Leveraging microRNAs for cellular therapy
Immunol Lett. 2023 Sep 1:S0165-2478(23)00143-8. doi: 10.1016/j.imlet.2023.08.005. Online ahead of print.ABSTRACTOwing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thu...
Source: Immunology Letters - September 3, 2023 Category: Allergy & Immunology Authors: Marko Hasiuk Marianne D ölz Romina Marone Lukas T Jeker Source Type: research
Leveraging microRNAs for cellular therapy
Immunol Lett. 2023 Sep 1:S0165-2478(23)00143-8. doi: 10.1016/j.imlet.2023.08.005. Online ahead of print.ABSTRACTOwing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thu...
Source: Immunology Letters - September 3, 2023 Category: Allergy & Immunology Authors: Marko Hasiuk Marianne D ölz Romina Marone Lukas T Jeker Source Type: research
Leveraging microRNAs for cellular therapy
Immunol Lett. 2023 Sep 1:S0165-2478(23)00143-8. doi: 10.1016/j.imlet.2023.08.005. Online ahead of print.ABSTRACTOwing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thu...
Source: Immunology Letters - September 3, 2023 Category: Allergy & Immunology Authors: Marko Hasiuk Marianne D ölz Romina Marone Lukas T Jeker Source Type: research
Leveraging microRNAs for cellular therapy
Immunol Lett. 2023 Sep 1:S0165-2478(23)00143-8. doi: 10.1016/j.imlet.2023.08.005. Online ahead of print.ABSTRACTOwing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thu...
Source: Immunology Letters - September 3, 2023 Category: Allergy & Immunology Authors: Marko Hasiuk Marianne D ölz Romina Marone Lukas T Jeker Source Type: research
Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model
CONCLUSIONS: The combination of Bap and BauA has the potential to target a broader range of A. baumannii strains, including those expressing either Bap or BauA, thereby increasing its efficacy against a diverse array of strains.PMID:37652189 | DOI:10.1016/j.imlet.2023.08.004 (Source: Immunology Letters)
Source: Immunology Letters - August 31, 2023 Category: Allergy & Immunology Authors: Mobina Mansouri Masoomeh Sadeghpoor Abolfazl Jahangiri Mohammad Hossein Ghaini Iraj Rasooli Source Type: research
Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model
CONCLUSIONS: The combination of Bap and BauA has the potential to target a broader range of A. baumannii strains, including those expressing either Bap or BauA, thereby increasing its efficacy against a diverse array of strains.PMID:37652189 | DOI:10.1016/j.imlet.2023.08.004 (Source: Immunology Letters)
Source: Immunology Letters - August 31, 2023 Category: Allergy & Immunology Authors: Mobina Mansouri Masoomeh Sadeghpoor Abolfazl Jahangiri Mohammad Hossein Ghaini Iraj Rasooli Source Type: research
